These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18501674)

  • 1. Docetaxel-related side effects and their management.
    Baker J; Ajani J; Scotté F; Winther D; Martin M; Aapro MS; von Minckwitz G
    Eur J Oncol Nurs; 2008 Jul; 12(3):253-68. PubMed ID: 18501674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel-related side effects and their management.
    Baker J; Ajani J; Scotté F; Winther D; Martin M; Aapro MS; von Minckwitz G
    Eur J Oncol Nurs; 2009 Feb; 13(1):49-59. PubMed ID: 19201649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.
    Colson K; Doss DS; Swift R; Tariman J; Thomas TE
    Clin J Oncol Nurs; 2004 Oct; 8(5):473-80. PubMed ID: 15515281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice.
    Wickham R
    Clin J Oncol Nurs; 2007 Jun; 11(3):361-76. PubMed ID: 17623621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing hematologic toxicities in the oncology patient.
    Montoya L
    J Infus Nurs; 2007; 30(3):168-72. PubMed ID: 17505218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses.
    Kearney N; Friese C
    Eur J Oncol Nurs; 2008 Feb; 12(1):14-25. PubMed ID: 18291720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy and cutaneous toxicities: implications for oncology nurses.
    Viale PH
    Semin Oncol Nurs; 2006 Aug; 22(3):144-51. PubMed ID: 16893743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical challenges: chemotherapy-induced peripheral neuropathy.
    Paice JA
    Semin Oncol Nurs; 2009 May; 25(2 Suppl 1):S8-19. PubMed ID: 19447319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncology nurses' use of National Comprehensive Cancer Network clinical practice guidelines for chemotherapy-induced and febrile neutropenia.
    Nirenberg A; Reame NK; Cato KD; Larson EL
    Oncol Nurs Forum; 2010 Nov; 37(6):765-73. PubMed ID: 21059588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboplatin hypersensitivity reactions.
    Winkeljohn D; Polovich M
    Clin J Oncol Nurs; 2006 Oct; 10(5):595-8. PubMed ID: 17063613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.
    Eckhoff L; Nielsen M; Moeller S; Knoop A
    Acta Oncol; 2011 Oct; 50(7):1075-82. PubMed ID: 21824038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation and management of peripheral neuropathy in diabetic patients with cancer.
    Visovsky C; Meyer RR; Roller J; Poppas M
    Clin J Oncol Nurs; 2008 Apr; 12(2):243-7. PubMed ID: 18390460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing side effects of the novel taxane cabazitaxel in castrate-resistant prostate cancer.
    Doyle-Lindrud S
    Clin J Oncol Nurs; 2012 Jun; 16(3):286-91. PubMed ID: 22641321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.
    Flowers CR; Seidenfeld J; Bow EJ; Karten C; Gleason C; Hawley DK; Kuderer NM; Langston AA; Marr KA; Rolston KV; Ramsey SD
    J Clin Oncol; 2013 Feb; 31(6):794-810. PubMed ID: 23319691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case report: painful peripheral neuropathy following treatment with docetaxel for breast cancer.
    Wampler MA; Hamolsky D; Hamel K; Melisko M; Topp KS
    Clin J Oncol Nurs; 2005 Apr; 9(2):189-93. PubMed ID: 15853162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current evidence on anticoagulant management and outcomes for postpolypectomy: an integrative literature review to assist advanced practice nurses.
    Ryle S
    Gastroenterol Nurs; 2008; 31(5):354-64. PubMed ID: 18849672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums.
    Smith EM; Cohen JA; Pett MA; Beck SL
    Cancer Nurs; 2010; 33(3):173-83. PubMed ID: 20357656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What kind of rash is it?: deciphering the dermatologic toxicities of biologic and targeted therapies.
    Esper P; Gale D; Muehlbauer P
    Clin J Oncol Nurs; 2007 Oct; 11(5):659-66. PubMed ID: 17962174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing drug infusion reactions: focus on cetuximab monoclonal antibody therapy.
    Wilkes G
    Clin J Oncol Nurs; 2008 Jun; 12(3):530-2. PubMed ID: 18515254
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of a protocol to minimize hypersensitivity reactions with asparaginase administration.
    Bryant R
    J Intraven Nurs; 2001; 24(3):169-73. PubMed ID: 11530362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.